The cellular prion protein (PrP^C^) is a ubiquitously expressed membrane-anchored protein encoded by the *Prnp* gene. Misfolding of PrP^C^ generates the scrapie prion protein (PrP^Sc^) and leads to a class of invariably lethal, neurodegenerative conditions termed transmissible spongiform encephalopathies, or prion diseases. Despite intense investigation and the availability of at least seven independently generated lines of *Prnp*^*−/−*^ mice, little is known about the physiological function of PrP^C^ ([@bib1]).

Two key genetic features of existing *Prnp*^*−/−*^ mouse lines constitute systematic experimental confounders that hampered the elucidation of the physiological role of PrP^C^ ([@bib44]). The first confounder stems from the design of *Prnp* targeting vectors. In four lines (*Prnp^Ngsk/Ngsk^*, *Prnp*^*Rcm0/Rcm0*^, *Prnp^Rkn/Rkn^*, and *Prnp^ZH2/ZH2^*) deletion of *Prnp* exon 3 spanning a splice acceptor site resulted in spurious overexpression of the *Prnd*-encoded Doppel protein, causing severe ataxia and Purkinje cell loss ([@bib44]). The second confounder depends on the embryonic stem (ES) cells and breeding schemes used for the generation of *Prnp*^*−/−*^ mice. All *Prnp*^*−/−*^ lines currently available have been generated in ES cells derived from the 129 strain of the laboratory mouse and are maintained in non-129 backgrounds, with the exception of the *Prnp^Edbg/Edbg^* line. Consequently, 129-derived genomic material flanking the targeted *Prnp* locus on chromosome 2 represents a systematic genetic confounder when *Prnp*^*−/−*^ and *Prnp^WT/WT^* mice are compared ([@bib35]; [@bib46]). In this study, we set out to overcome these limitations by generating a co-isogenic line of *Prnp*^−/−^ mice in the well-characterized C57BL/6J background using transcription activator-like effector nuclease (TALEN)--based genome editing.

RESULTS AND DISCUSSION {#s01}
======================

TALEN-induced disruption of the *Prnp* protein-coding sequence {#s02}
--------------------------------------------------------------

The complete protein-coding DNA sequence (CDS) for mouse PrP^C^ is located within exon 3 of the *Prnp* gene. To eliminate PrP^C^ expression in C57BL/6J without disrupting the *Prnp* gene architecture, we used a TALEN pair targeting a site within the *Prnp* CDS in close proximity to the start codon ([Fig. 1 A](#fig1){ref-type="fig"}). 1 of 44 F~0~ pups was found to carry a *Prnp* allele with an 8-bp deletion (termed *Prnp^ZH3^*). The frame shift within *Prnp^ZH3^* introduced a premature stop codon in the sequence coding for the PrP^C^ secretory signal peptide ([Fig. 1 B](#fig1){ref-type="fig"}). *Prnp^ZH3^* was efficiently transmitted through the germ line, and mice homozygous for *Prnp^ZH3^* were obtained in the F~2~ generation (C57BL/6J-*Prnp^ZH3/ZH3^*, hereafter termed *Prnp^ZH3/ZH3^*), as assessed by restriction fragment length polymorphism (RFLP) analysis and TaqMan-based allelic discrimination assay ([Fig. 1, C and D](#fig1){ref-type="fig"}).

![**TALEN-based generation of C57BL/6J-*****Prnp^ZH3/ZH3^*** **mice.** (A) TALEN-binding sites within *Prnp* exon E3 and start codon (yellow) of the protein coding sequence. Colors indicate the code for repeat-variable diresidues. The *Prnp* TALEN pair incorporates second-generation heterodimeric *FokI* cleavage domains (*FokI^ELD^* and *FokI^KKR^*). (B) Sanger sequencing reads of a *Prnp^WT^* and a *Prnp^ZH3^* allele from the founder F~0~ mouse. A deletion of 8 bp in the *Prnp^ZH3^* allele (highlighted by a red box on the WT sequence) introduces a T/D residue change, followed by a premature STOP codon (\*) after residue 14 within the sequence encoding the PrP^C^ signal peptide. The deletion also eliminates the Tsp45I recognition sequence (blue letters on WT sequence). As a result of sequence characteristics in this region, an alternative 8-bp deletion (ACTATGTG), shifted by 4 bp in respect to the previous deletion, is also compatible with the generation of the *Prnp^ZH3^* allele. (C) Representative image of routinely used RFLP analysis discriminating *Prnp^WT/WT^* (digested amplicons), *Prnp^WT/ZH3^* (digested and undigested amplicons), and *Prnp^ZH3/ZH3^* mice (only undigested amplicon). Primers location, restriction site, and expected sizes for digestion products are indicated on top of the gel image. (D) Allelic discrimination genotyping using a FAM-labeled WT-specific probe and a Yakima Yellow--labeled ZH3-specific probe. NTC, no-template control. ΔRn, difference in normalized reporter fluorescence after and before amplification. Apart from NTC, each triangle denotes one mouse (*n* = 4 mice/genotype). The mean (triangle) and SD (blue error bars) for four technical replicates of each mouse/NTC sample are shown. (E) Immunoblot analysis of PrP^C^ expression in different CNS regions (Cx, cortex; Sc, spinal cord; Cb, cerebellum) of *Prnp^WT/WT^* (WT) and *Prnp^ZH3/ZH3^* (ZH3) mice was performed using POM1 (against helices α1 and α3 of the PrP^C^ globular domain). The blot was also decorated with anti-actin antibody as control. (F) Brain PrP^C^ levels as determined by sandwich POM1-POM2 ELISA. *Prnp^Edbg/Edbg^* (Edbg) served as negative controls. Each circle denotes a mouse (*n* = 3 mice/genotype). Horizontal bar indicates mean. WT→KO, consecutive log~2~ dilutions of *Prnp^WT/WT^* into *Prnp^Edbg/Edbg^* homogenate, indicating that the threshold of detectability was 1:16. (G) Immunofluorescence staining of cerebelli. MAP2 is displayed in green, PrP^C^, detected with POM19 (against helices β1 and α3 of globular domain) in red, and DAPI in blue. Bar, 20 µm. (D--G) Representative data from two independent experiments.](JEM_20151610_Fig1){#fig1}

As expected, *Prnp^ZH3/ZH3^* mice showed no detectable PrP^C^ expression in central nervous system (CNS) tissues, as assessed by Western blotting ([Fig. 1 E](#fig1){ref-type="fig"}), by a high sensitivity sandwich ELISA ([Fig. 1 F](#fig1){ref-type="fig"}) or by immunofluorescence ([Fig. 1 G](#fig1){ref-type="fig"}). Collectively, these data indicate that a TALEN-induced deletion of 8 bp within *Prnp* results in a functional disruption of the *Prnp* CDS and abolishes the competence for PrP^C^ expression.

Analysis of TALEN off-target cleavage and chromosomal aberrations {#s03}
-----------------------------------------------------------------

TALENs do not typically cause extensive genomic off-target modifications. However, cleavage of closely related off-target sites (OTs) can occur ([@bib17]). We PCR amplified eight potential OTs from the TALEN-targeted founder and a C57BL/6J control ([Tables S1 and S2](http://www.jem.org/cgi/content/full/jem.20151610/DC1){#supp1}). Amplicons were subjected to an annealing protocol that enables the formation of heteroduplexes in the presence of heterozygous mutations. Treatment of these reannealed amplicons with T7 endonuclease I, which cleaves heteroduplexes, did not yield any digestion products indicative of TALEN off-target cleavage ([Fig. 2](#fig2){ref-type="fig"}).

![**C57BL/6-*****Prnp^ZH3/ZH3^*** **mice do not have TALEN off-target cleavage sites.** T7 endonuclease I digestion of PCR products generated from predicted OTs ([Table S1](http://www.jem.org/cgi/content/full/jem.20151610/DC1){#supp2}) and *Prnp* as a digestion positive control. Analyses were performed on the founder *Prnp*^*WT/ZH3*^ mouse and one control C57BL/6J mouse. Before enzymatic digestion, amplicons were subjected to a temperature gradient enabling the formation of heteroduplexes in the presence of heterozygous mutations in the amplified gDNA. In the presence of TALEN-induced mutations, fragments of the size indicated below the gels are expected to appear, in addition to the undigested, WT amplicon. Nonconsecutive lanes from the same gel show *Prnp* amplicon as a control. Only in the founder *Prnp*^*WT/ZH3*^ mouse T7 endonuclease I digestion of the *Prnp* amplicon results in the formation of the two predicted fragments (indicated by an asterisk).](JEM_20151610_Fig2){#fig2}

We next investigated the presence of chromosomal abnormalities in the *Prnp^ZH3/ZH3^* line. Giemsa banding (G-banding) and spectral karyotyping showed a normal 40X,Y karyotype ([Fig. S1 A](http://www.jem.org/cgi/content/full/jem.20151610/DC1){#supp3}) in 14/25 metaphases from a fibroblast cell line obtained from a *Prnp^ZH3/ZH3^* mouse. The remaining karyotyped metaphases showed some degrees of chromosomal aberrations, including six metaphases with 79 or 80 chromosomes, possibly representing cell culture artifacts ([@bib31]). To account for this possibility, we performed G-banding analysis of primary splenocytes from another *Prnp^ZH3/ZH3^* mouse. Here, we found a normal 40X,Y karyotype in 35/35 metaphases. These analyses excluded the presence of large TALEN-induced chromosomal aberrations.

We then performed high-density array comparative genomic hybridization (aCGH). This analysis showed the presence of a relative loss of genomic DNA (gDNA) in one *Prnp^ZH3/ZH3^* mouse compared with one C57BL/6J control mouse in a 34.4-kbp region of chromosome 16 encompassing the *Maats1* locus (Fig. S1 B). This could reflect either a genomic loss in the *Prnp^ZH3/ZH3^* mouse or a genomic gain in the C57BL/6J mouse. Copy number variants (CNVs) are frequently observed among different individuals of the same inbred colony of laboratory mice, including C57BL/6J, and de novo CNV occur with an incidence of 1--14% ([@bib18]; [@bib20]). Therefore the degree of genomic variation between the two analyzed *Prnp^ZH3/ZH3^* and C57BL/6J individual mice is not dissimilar to the variation seen between different individuals of the C57BL/6J strain and falls within the natural genetic variation of inbred strains of the laboratory mouse. Importantly, we did not identify any structural change linked to the targeted *Prnp* locus on chromosome 2, which would represent a systematic confounder in studies comparing *Prnp^ZH3/ZH3^* and *Prnp^WT/WT^* mice.

*Prnp^ZH3/ZH3^* mice lack the flanking gene problem {#s04}
---------------------------------------------------

We next studied the genomic background of *Prnp^ZH3/ZH3^* mice. Whole-genome single-nucleotide polymorphism (SNP) analysis of *Prnp^ZH3/ZH3^* confirmed that 100% of the analyzed markers were of the C57BL/6J type ([Fig. S2](http://www.jem.org/cgi/content/full/jem.20151610/DC1){#supp4}). To further investigate the genomic similarity of *Prnp^ZH3/ZH3^* mice with C57BL/6J mice, we performed RNA sequencing in hippocampi of 3-mo-old male mice. For additional comparison, we analyzed hippocampi from congenic aged-matched *Prnp^ZH1/ZH1^* males that had been backcrossed for \>12 generations to the C57BL/6 background.

In comparison with C57BL/6J mice, *Prnp^ZH1/ZH1^* showed a significantly higher number of variants than *Prnp^ZH3/ZH3^* (mean number of variants, including SNPs and insertions/deletions, INDEL: 3,343 versus. 373; P \< 0.01, Student's *t* test; [Fig. 3 A](#fig3){ref-type="fig"}). Notably, the 373 variants detected in *Prnp^ZH3/ZH3^* included the 8-bp deletion within *Prnp* exon 3 (position chr2:131936464) characteristic of the *Prnp^ZH3^* allele, confirming the accuracy of our procedure for variant identification ([Fig. S3](http://www.jem.org/cgi/content/full/jem.20151610/DC1){#supp5}). By plotting the density of sequence variation against its genomic location, we observed an obvious clustering of variants in chromosome 2 of *Prnp^ZH1/ZH1^* mice, with \>90% of variants in this chromosome, as expected from the inevitable flanking-gene artifacts derived from the targeting and breeding strategies in these mice. Crucially, no such clustering was observed in *Prnp^ZH3/ZH3^* mice ([Fig. 3 A](#fig3){ref-type="fig"}).

![**RNA sequencing in** ***Prnp^WT/WT^*****,** ***Prnp^ZH1/ZH1^*****, and** ***Prnp^ZH3/ZH3^*** **hippocampi.** RNA sequencing was performed on hippocampi from four mice per each group. (A) Physical distribution of sequence variant density across the genome based on variants unique to *Prnp^ZH1/ZH1^* (ZH1, left) or *Prnp^ZH3/ZH3^* (ZH3, right) compared with C57BL/6J mice (BL6). Each dot denotes the ratio of variants and total number of annotated bases in 50-kb windows throughout the genome. Pie charts depict the number (*n*, proportional to the area) and chromosomal distribution (yellow, chromosome 2; gray, other chromosomes) of sequence variants in the two comparisons. For variant identification, the three mice with the highest coverage within each group were considered. (B) Physical distribution of differential gene expression levels across the genome based on the comparison of *Prnp^ZH1/ZH1^* (left) or *Prnp^ZH3/ZH3^* (right) with respect to C57BL/6J mice. Each dot denotes a gene. Pie charts depict the number (*n*, proportional to the area) and chromosomal distribution (yellow, chromosome 2; gray, other chromosomes) of DEGs (fdr \< 0.05 and absolute log2 ratio \> 0.5) in the two comparisons.](JEM_20151610_Fig3){#fig3}

We then sought to identify genes differentially expressed between *Prnp^ZH1/ZH1^* or *Prnp^ZH3/ZH3^* versus C57BL/6J hippocampi. The mean *Prnp* mRNA levels were significantly higher in C57BL/6J hippocampi (17,538 reads per kilobase per million mapped reads \[RPKM\]) than in *Prnp^ZH1/ZH1^* (5,781 RPKM, false discovery rate \[fdr\]: 3.98 × 10^−85^) and *Prnp^ZH3/ZH3^* hippocampi (13,278 RPKM, fdr \< 0.01; Fig. S3). Conversely, C57BL/6J, *Prnp^ZH1/ZH1^* or *Prnp^ZH3/ZH3^* did not differ in their mean *Prnd* levels (4 RPKM, 5 RPKM, and 2 RPKM, respectively), nor in their mean *Matts1* levels (26 RPKM, 22 RPKM, and 18 RPKM, respectively). The latter observation excludes a systematic loss of genomic material comprising the *Matts1* locus in the *Prnp^ZH3/ZH3^* colony. Importantly, we did not identify any gene transcribed in C57BL/6J or *Prnp^ZH1/ZH1^* hippocampi that was not detectable in *Prnp^ZH3/ZH3^* hippocampi. This observation excludes the presence of deletions \>100 bp (and as such not detectable with our variant identification strategy based on sequencing short reads) induced by TALEN in the fraction of the *Prnp^ZH3/ZH3^* genome inferred from the hippocampus transcriptome.

When plotting the differential expression levels of all detectable genes against their genomic location, *Prnp^ZH1/ZH1^* showed obvious clustering of up- and down-regulated genes versus C57BL/6J on chromosome 2 ([Fig. 3 B](#fig3){ref-type="fig"}). We then focused on differentially expressed genes (DEGs) with fdr \< 0.05 and absolute log~2~ ratio \> 0.5. Using these filters, we detected a significant enrichment of chromosome 2 genes with differential expression level in *Prnp^ZH1/ZH1^* (82 genes, 35 of which resided on chromosome 2) as opposed to *Prnp^ZH3/ZH3^* mice compared with the same C57BL/6J controls (14 genes, none of which resided on chromosome 2; P = 0.02, Fisher's exact test, [Fig. 3 B](#fig3){ref-type="fig"}). Only two genes are shared between these two lists ([Tables S3 and S4](http://www.jem.org/cgi/content/full/jem.20151610/DC1){#supp6}). This enrichment may reflect sequence variations in regulatory elements present in the 129-genomic region introgressed in the genome of *Prnp^ZH1/ZH1^* mice, which results in increased or reduced expression of neighboring genes (cis-expression quantitative trait loci \[eQTL\]; [@bib27]). This phenomenon is likely to underlie the enrichment of chromosome 2 genes among the DEGs between congenic *Prnp^ZH1/ZH1^* mice and matched WT mice in previous microarray-based transcriptomic analyses ([@bib10]; [@bib3]). A similar phenomenon can be seen in congenic lines for other genes, where the chromosome bearing the targeted gene is the one with the highest number of DEGs between the congenic knockout and WT mice ([@bib19]), even though the lack of comparison with a co-isogenic mouse does not allow concluding whether this effect is a result of the flanking gene problem or not. Also, it is plausible that this effect can become less apparent depending on the functional consequence of the gene under investigation and the experimental setup used ([@bib32]).

Next, we analyzed alternative splicing by assessing the presence of differential exon usage between *Prnp^ZH1/ZH1^* or *Prnp^ZH3/ZH3^* versus C57BL/6J hippocampi. We applied similar stringent filters used to identify DEGs (with adjusted P value \< 0.05 and absolute log~2~ ratio \> 0.5). Interestingly, we found no genes with differential exon usage in *Prnp^ZH3/ZH3^* mice compared with C57BL/6J with the applied filters. Conversely, 9 exons, belonging to 7 genes (6 of which were on chromosome 2), were differentially expressed between *Prnp^ZH1/ZH1^* and C57BL/6J mice ([Table S5](http://www.jem.org/cgi/content/full/jem.20151610/DC1){#supp7}). This enrichment of chromosome 2 genes among genes with differential exon usage in *Prnp^ZH1/ZH1^* versus C57BL/6J hippocampi likely reflects the presence of sequence variants affecting alternative splicing of neighboring genes ([@bib26]; [@bib13]). Indeed, the lack of enrichment of chromosome 2 genes for loci undergoing differential expression or exon usage in *Prnp^ZH3/ZH3^* versus C57BL/6J hippocampi excludes its dependence from *Prnp* genetic ablation and conversely suggests that this is yet another, often neglected, genetic confounder of studies with non--co-isogenic knockout mice ([@bib47]).

We next analyzed the impact of *Prnp* genetic ablation in vivo on various aspects of RNA metabolisms. Besides genes with differential expression and exon usage, we analyzed transcripts undergoing RNA editing. By comparing transcript sequences to reference genomic sequences and to published databases of RNA-editing sites in mice, we found 271 sites with evidence for RNA editing in *Prnp^ZH1/ZH1^*, *Prnp^ZH3/ZH3^*, and/or C57BL/6J hippocampi. Compared with C57BL/6J, three sites in *Prnp^ZH1/ZH1^* and seven sites in *Prnp^ZH3/ZH3^* hippocampi showed a significantly different level of RNA editing (P \< 0.05; [Fig. 4, A and B](#fig4){ref-type="fig"}; and [Tables S6 and S7](http://www.jem.org/cgi/content/full/jem.20151610/DC1){#supp8}). We then selected three of these sites (mapped to *Gria2*, *Grik2*, and *Rbm4b*) and performed Sanger sequencing of gDNA from the mice included in the RNA sequencing experiment. This analysis confirmed the presence, in homozygosity, of the expected, reference nucleotide ([Fig. S4](http://www.jem.org/cgi/content/full/jem.20151610/DC1){#supp9}), thereby excluding that the observed mismatch in the RNA reads might be a result of DNA polymorphisms, rather than RNA editing. In all cases in which sites could be assigned to a gene, edited sites were found to be present in noncoding regions. Also, in all but one of these cases, one adenosine in the reference genome was found to be replaced by a guanosine in the sequenced reads ([Fig. 4 B](#fig4){ref-type="fig"}), which is in line with an adenosine-to-inosine RNA-editing process ([@bib30]). Sites with differential RNA editing between C57BL/6J and *Prnp^ZH3/ZH3^* hippocampi included two intronic sites belonging to genes (*Grik2* and *Gria2*) encoding for members of the kainate family of glutamate receptors ([Fig. 4 B](#fig4){ref-type="fig"}). RNA editing in these intronic positions of these genes have been previously reported ([@bib45]), whereas editing in the coding regions of *Grik2* and *Gria2* transcripts significantly affects protein function ([@bib42]; [@bib41]). It will be of interest to test whether any of these changes might be related to the currently debated role of PrP^C^ in kainate-induced excitotoxicity ([@bib46]; [@bib8]).

![**Impact of *Prnp* genetic ablation on RNA metabolism in vivo.** RNA sequencing was performed on hippocampi from four mice per each group. (A) Pie charts depict the number (proportional to the area) of genes showing differential expression (expression), exon usage (splicing), or RNA editing levels (editing) between *Prnp^ZH1/ZH1^* (ZH1, left) or *Prnp^ZH3/ZH3^* (ZH3, right) and C57BL/6J mice. Colors indicate genes known to be enriched in specific cell types of the central nervous system. (B) Sites with differential RNA-editing levels between *Prnp^ZH1/ZH1^* (left) or *Prnp^ZH3/ZH3^* (right) and C57BL/6J mice. Editing level indicates percentage of reads showing an edited base instead of the canonical base. Each dot denotes one mouse. This analysis is based on the three mice with the highest coverage for each group. Horizontal bar indicates mean. For sites assigned to a gene (indicated with the gene name), the lower nucleotide indicates the edited base and the upper nucleotide the reference base. The other sites are indicated with their genomic location. One site (indicated as *Ovca2*) is mapped to two neighboring genes (*Ovca2* and *Mir684-1*) on the same strand. (C) Heat map of genes with differential expression levels between *Prnp^ZH1/ZH1^* (left) or *Prnp^ZH3/ZH3^* (right) and C57BL/6J mice. Each row represents one mouse. Two genes (*Tmem-181b-ps* and *Tmem-181c-ps*) are common to both comparisons.](JEM_20151610_Fig4){#fig4}

In the case of *Prnp^ZH1/ZH1^* versus C57BL/6J hippocampi, there was one gene, *Wdr76*, on chromosome 2, with evidence of both differential expression and exon usage ([Fig. 4 A](#fig4){ref-type="fig"} and Tables S3 and S5). No such changes were detected between *Prnp^ZH3/ZH3^* and C57BL/6J hippocampi. *Wdr76* is mapped on chromosome 2, ∼10 Mb apart from *Prnp*, and is highly polymorphic between C67BL/6 and 129 strains, with numerous SNPs between these strains, including a coding nonsynonymous one (rs27425186; Mouse Phenome Database). Interestingly, *Wdr76* plays a role in the recovery from genotoxic stress ([@bib21]) and congenic B6.129-*Prnp^ZH1/ZH1^* mice have been recently shown to have a defective repair of induced DNA damage in the brain compared with C57BL/6N WT mice ([@bib4]). It will be of interest to investigate to what extent the observed phenotype can be influenced by differences in *Wdr76* expression, splicing and coding sequence between the two examined genotypes.

A subset of genes with differential expression is represented by transcripts known to be enriched in different cell types of the CNS ([Fig. 4 A](#fig4){ref-type="fig"}). When analyzing the 82 genes found to be differentially expressed between C57BL/6J and *Prnp^ZH1/ZH1^* hippocampi, *Prnp^ZH3/ZH3^* showed an overall pattern of expression closer to the one of C57BL/6J hippocampi ([Fig. 4 C](#fig4){ref-type="fig"}). Analogously, for the 14 DEGs between C57BL/6J and *Prnp^ZH3/ZH3^* hippocampi, *Prnp^ZH1/ZH1^* showed an overall expression profile closer to the one of C57BL/6J hippocampi. Pathway analysis based on these 14 DEGs did not identify any canonical pathway associated with more than 2 DEGs. However, it is of interest that several of these 14 DEGs are associated with immunological functions (e.g., *Icam1*, *C1qb*, *Itga7*, *Sele*, and *Spsb1*).

Collectively, these observations highlight, at a molecular level, that congenic *Prnp^ZH1/ZH1^* and co-isogenic *Prnp^ZH3/ZH3^* mice are largely divergent and that, in *Prnp^ZH1/ZH1^* mice, a conspicuous proportion of the observed transcriptional changes is related to genes on chromosome 2, where an ES cell--derived genomic region (of 129 type) is retained. Moreover, these data confirm that *Prnp^ZH3/ZH3^* mice have a bona fide C57BL/6J genome, including the region flanking *Prnp*, and therefore are devoid of the flanking gene problem affecting other non--co-isogenic lines.

*Prnp^ZH3/ZH3^* macrophages do not show enhanced phagocytic activity {#s05}
--------------------------------------------------------------------

Hyperphagocytosis of apoptotic cells in primary macrophages from non--co-isogenic *Prnp*^*−/−*^ lines was originally attributed to the absence of *Prnp* ([@bib14]), but was later shown to be the result of a flanking gene problem ([@bib35]). We measured the phagocytic activity of primary BM-derived C57BL/6J and *Prnp^ZH3/ZH3^* macrophages exposed to apoptotic thymocytes. Congenic *Prnp^ZH1/ZH1^* macrophages were included as controls. In line with our previous observations ([@bib35]), we found increased phagocytic activity only in *Prnp^ZH1/ZH1^* macrophages, but not in *Prnp^ZH3/ZH3^* macrophages ([Fig. 5 A](#fig5){ref-type="fig"} and Fig. S5).

![**C57BL/6J-*****Prnp^ZH3/ZH3^*** **mice do not show artifactual phenotypes of other** ***Prnp^−/−^*** **lines.** (A) Rate of phagocytosis of BMDM obtained from C57BL/6J (BL6) and *Prnp^ZH3/ZH3^* mice (ZH3) and exposed to different numbers of apoptotic thymocytes (indicated as thymocytes to BMDM ratios). Macrophages from *Prnp^ZH1/ZH1^* mice (ZH1) served as control. Each dot denotes a macrophage well exposed to thymocytes (*n* = 8 macrophage wells/genotype/condition). Values were normalized to the rate of phagocytosis in C57BL/6J mice with 10 thymocytes to BMDM ratio (mean set as 100%). Horizontal bar indicates mean. Data are from two independent experiments. n.s.: not significant; two-way ANOVA, Bonferroni's multiple comparisons test. (B) Representative images of footprints from 10--14-mo-old *Prnp^WT/WT^* and *Prnp^ZH3/ZH3^* mice. Magenta, fore paw; blue, hind paw. (C) Quantification of different gait parameters. Each circle denotes a mouse (*n* = 6 mice/genotype). Horizontal bar indicates mean. n.s., not significant; Student's *t* test. (B and C) are representative data from two/three trials. (D) Latency to fall at the rotarod test in *Prnp^WT/WT^* and *Prnp^ZH3/ZH3^* mice. Mice were 10--14-mo-old at test 1 and test 2 was performed 1 mo after. Each circle denotes a mouse (*n* = 6 mice/genotype). Horizontal bar indicates mean. n.s., no significant difference between genotypes, two-way ANOVA. (E) Representative images of hematoxylin and eosin (H & E) staining of cerebelli of 60-wk-old *Prnp^WT/WT^* and *Prnp^ZH3/ZH3^* mice (*n* = 3 and 8 mice, respectively). 63-wk-old *Prnp^ZH2/ZH2^* mice served as control (*n* = 2 mice). Bar, 50 µm. Data are from two experiments. (F) Brain *Prnd* mRNA levels as determined by qRT-PCR. Values were normalized to levels in testis of *Prnp^WT/WT^* mice (mean set as 1). *Prnp^Edbg/Edbg^* (Edbg) and *Prnp^Ngsk/Ngsk^* (Ngsk) served as negative and positive controls, respectively. Each circle denotes a mouse (*n* = 4 mice for Ngsk and *n* = 3 mice for all other genotypes). Horizontal bar indicates mean.](JEM_20151610_Fig5){#fig5}

*Prnp^ZH3/ZH3^* mice do not display Prnd overexpression and associated neurodegeneration {#s06}
----------------------------------------------------------------------------------------

Purkinje cell degeneration in the cerebellum and associated ataxia, starting from the age of 6 mo, is a hallmark of several lines of *Prnp*-ablated mice and is caused by inappropriate intergenic splicing and overexpression of the neighboring *Prnd* gene ([@bib34]). We monitored *Prnp^ZH3/ZH3^* mice for the occurrence of similar neurodegenerative changes. 10--14-mo-old *Prnp^WT/WT^* and *Prnp^ZH3/ZH3^* littermates showed similar walking patterns as assessed by the footprint test ([Fig. 5, B and C](#fig5){ref-type="fig"}), and similar performance in the rotarod test ([Fig. 5 D](#fig5){ref-type="fig"}). At 15 mo of age, no significant loss of Purkinje cells was evident ([Fig. 5 E](#fig5){ref-type="fig"}). Also, quantitative real-time PCR (qRT-PCR) showed brain levels of *Prnd* transcripts similar between *Prnp^WT/WT^* and *Prnp^ZH3/ZH3^* mice ([Fig. 5 F](#fig5){ref-type="fig"}), in line with the RNA sequencing data. Collectively, these data indicate that *Prnp^ZH3/ZH3^* mice did not experience any significant perturbation of *Prnd* expression and its associated neurodegeneration observed in four of the previously generated *Prnp*^*−/−*^ lines.

*Prnp^ZH3/ZH3^* mice develop a chronic demyelinating peripheral neuropathy {#s07}
--------------------------------------------------------------------------

Progressive chronic demyelinating polyneuropathy (CDP) is a robust phenotype present in all examined *Prnp*^*−/−*^ lines, including co-isogenic *Prnp^Edbg/Edbg^* mice, and results from the absence of neuronal PrP^C^ expression ([@bib5]). We analyzed the integrity of peripheral nerves in *Prnp^ZH3/ZH3^* mice and found a trend toward increased CD68^+^ digestion chambers (indicative of myelin degradation and resorption by macrophages) in the sciatic nerves of 3-mo-old *Prnp^ZH3/ZH3^* mice that reached statistical significance at 9 mo ([Fig. 6, A and B](#fig6){ref-type="fig"}). At 14 mo of age, *Prnp^ZH3/ZH3^* mice showed a significant reduction of axonal density in sciatic nerves as compared with *Prnp^WT/WT^* ([Fig. 6, C and D](#fig6){ref-type="fig"}), as well as ultrastructural signs of demyelination ([Fig. 6 E](#fig6){ref-type="fig"}). All these features strongly resemble the changes described in sciatic nerves of other previously examined *Prnp*^*−/−*^ lines and confirm the crucial involvement of PrP^C^ in peripheral myelin maintenance ([@bib5]).

![**C57BL/6J-*****Prnp^ZH3/ZH3^*** **mice develop a chronic demyelinating peripheral neuropathy.** (A) Representative images of CD68 staining of longitudinal sections of sciatic nerves show digestion chambers of macrophages and myelin debris in *Prnp^ZH1/ZH1^* (ZH1), *Prnp^ZH3/ZH3^* (ZH3), and *Prnp^WT/WT^*(WT) mice at 3 and 9 mo of age. Bar, 50 µm. (B) Corresponding quantification of CD68^+^ digestion chambers in sciatic nerves at the same time points as in A. Each dot denotes a mouse (*n* = 4--6 mice/genotype/time point). Horizontal bar indicates mean. n.s., not significant; \*\*\*\*, P \< 0.0001. One-way ANOVA, Bonferroni's multiple comparisons test. (C) Representative images of toluidine blue staining of semi-thin cross-sections of sciatic nerves from *Prnp^WT/WT^* and *Prnp^ZH3/ZH3^* mice at 14 mo of age. Bar, 50 µm. (D) Corresponding quantification of density of axons of different size in sciatic nerves of 14-mo-old mice (WT, *n* = 3 mice; ZH3, *n* = 8 mice). Symbols indicate mean, whiskers indicate minimum and maximum values. Two-way ANOVA shows a significant effect (P \< 0.0001) of genotype. (E) Representative images of transmission electron microscopy of cross sections from sciatic nerves of 14-mo old mice (WT, *n* = 3 mice; ZH3, *n* = 4 mice). Arrows indicate thinly myelinated axons. Bar, 10 µm. (A--E) Data from two experiments.](JEM_20151610_Fig6){#fig6}

*Prnp^ZH3/ZH3^* mice as a genetic resource for prion science {#s08}
------------------------------------------------------------

Overall, these data confirm that *Prnp^ZH3/ZH3^* mice lack the genetic confounders and artifactual phenotypes of non--co-isogenic *Prnp*^*−/−*^ lines. Because of the stringent genetic controls described above, *Prnp^ZH3/ZH3^* mice constitute an unprecedented genetic tool for elucidating the physiological function of PrP^C^ and its involvement in pathological conditions. This line will be particularly well suited to intercrossing and/or comparing with other genetically modified mice raised on the well-characterized C57BL/6 background. Our institution will be pleased to provide unrestricted access to *Prnp^ZH3/ZH3^* mice for noncommercial purposes.

The strategy exemplified in the generation and characterization of *Prnp^ZH3/ZH3^* mice carries implications beyond the prion community. The majority of studies involving knockout mice are based on non--co-isogenic, ES cell--derived knockout lines. However, unmatched genetic background between such knockout mice and WT counterparts (even when using littermates from heterozygous breedings) is unavoidable in these cases and this situation often gives rise to serious and systematic genetic confounders ([@bib48]). Common efforts to target each gene of the mouse genome in C57BL/6-derived ES cells ([@bib12]) represent a valid strategy to prevent these problems. Moreover, the recent availability of genome-editing techniques, including the TALEN technique presented here, is now enabling the rapid and simple manipulation of the mouse genome. Our study demonstrate that this approach may also be applicable to genes for which knockout mice are already available (and extensively characterized), thereby generating improved genetic models and disproving potentially misattributed physiological functions.

MATERIALS AND METHODS {#s09}
=====================

 {#s10}

### Ethical statement {#s11}

Animal care and experimental protocols were performed in compliance with the Swiss Ethical Principles and Guidelines for Experiments on Animals, the Swiss Animal Protection Law, and with the internal guidelines of the University of Zurich, under the approval of the Veterinary Office of the Canton Zurich (animal permits Versuchstierhaltung 123, 90/2013). All efforts were made to minimize animal discomfort and suffering.

### Mice {#s12}

The following mice were studied: *Prnp^ZH1/ZH1^* mice ([@bib6]) backcrossed to C57BL/6 for \>12 generations; *Prnp^ZH2/ZH2^* mice ([@bib39]) on a mixed B6129 background; *Prnp^Edbg/Edbg^* mice on a pure 129/Ola background ([@bib33]) and co-isogenic WT 129/Ola mice, both provided by J. Manson, H. Baybutt, and N.A. Mabbott (University of Edinburgh, Edinburgh, Scotland, UK); *Prnp^Ngsk/Ngsk^* mice ([@bib40]) extensively backcrossed to C57BL/6; *Prnp^GFP/GFP^* mice ([@bib24]) backcrossed to C57BL/6 for 10 generations provided by W. Jackson (Deutsches Zentrum für Neurodegenerative Erkrankungen, Bonn, Germany) and S. Lindquist (Massachusetts Institute of Technology, Cambridge, MA); WT C57BL/6J and Crl:CD1(ICR) mice purchased from The Jackson Laboratory, Charles River, or bred in-house. Genetically vasectomized mice ([@bib23]) were maintained in house. Genotypes were verified by PCR on DNA obtained from ear punches as indicated in the original description of each line. All animals were maintained in temperature- and light-controlled rooms (12 light/12 dark) with food and water ad libitum in a high-hygienic grade facility. Mice were euthanized by cervical dislocation, followed by decapitation, or anesthetized with ketamine-xylazine and transcardially perfused with a solution of PBS containing heparin, unless otherwise specified. Archival material, including paraffin-embedded tissues and gDNA samples originally described in previous studies ([@bib22]; [@bib35]), was also analyzed. Archival gDNA samples included material provided by the Institute of Physical and Chemical Research (Saitama, Japan).

### Genome editing in mouse embryos {#s13}

Design of TALEN-targeting strategy was based on the employment of second-generation heterodimeric FokI cleavage domains fused to a truncated TALE C terminus for improved specificity and cleavage efficiency and microinjections were performed as previously described ([@bib25]).

The TALEN target sites 5′-TGGCTGCTGGCCCTCT-3′ and 5′-TGCAGAGGCCGACATCA-3′ within the *Prnp* protein coding sequence were identified using the TALEN-NT algorithm ([@bib17]). TALE-NT was also used to predict potential OTs for the *Prnp* TALEN pair and the 8 PCR-accessible out of the 12 top-scoring sites were selected for further analysis. TALENs were assembled using the Golden Gate TALEN and TAL Effector kit (plasmid kit 1000000024; Addgene; [@bib9]) and the pCAG-T7 heterodimeric TALEN destination vectors (plasmids 40131 and 40132; Addgene; [@bib25]). In vitro mRNA transcription, capping, and polyadenylation were performed using the mMESSAGE mMACHINE T7 Ultra kit. Before injection, the mRNAs were purified using NucAway Spin Columns (Ambion). mRNA quality was verified by denaturing gel electrophoresis; concentration was determined by spectrophotometry. Microinjection of C57BL/6J embryos with *Prnp* TALEN mRNAs at a concentration of 100 ng/µl resulted in gene modification in \>40% of founder animals as previously described ([@bib25]). In the present study, a concentration of 10 ng/µl was employed. C57BL/6J female mice underwent ovulation induction by i.p. injection of 5 IU equine chorionic gonadotrophin (PMSG; Folligon--InterVet), followed by i.p. injection of 5 IU human chorionic gonadotropin (Pregnyl--Essex Chemie) 48 h later. For the recovery of zygotes, C57BL/6J females were mated with males of the same strain immediately after the administration of human chorionic gonadotropin. All zygotes were collected from oviducts 24 h after the human chorionic gonadotropin injection, and were then freed from any remaining cumulus cells by a 1--2 min treatment of 0.1% hyaluronidase (Sigma-Aldrich) dissolved in M2 medium (Sigma-Aldrich). Mouse embryos were cultured in M16 (Sigma-Aldrich) medium at 37°C and 5% CO~2~. For micromanipulation, embryos were transferred into M2 medium.

All microinjections were performed using a microinjection system comprised of an inverted microscope equipped with Nomarski optics (Nikon), a set of micromanipulators (Narashige), and a FemtoJet microinjection unit (Eppendorf). TALEN mRNAs were injected at a concentration of 10 ng/µl into the cytoplasm of fertilized mouse oocytes. Embryos that survived the microinjection were transferred on the same day into the oviducts of 8--16-wk-old pseudopregnant Crl:CD1(ICR) females (0.5 d used after coitus) that had been mated with sterile genetically vasectomized males ([@bib23]) the day before embryo transfer. Pregnant females were allowed to deliver and raise their pups until weaning age.

### Identification of nonhomologous end-joining--modified alleles {#s14}

gDNA was extracted from tissue biopsies using a buffer containing 10 mM Tris-HCl, pH 9.0, 50 mM KCl, 0.45% Nonident p40, 0.45% Tween-20, and Proteinase K. For detecting nonhomologous end-joining--mediated insertions/deletions, amplicons of the *Prnp* locus and selected potential TALEN off-target cleavage sites were generated using appropriate primers (listed in Table S2) and Herculase II Fusion DNA Polymerase (Agilent Technologies) using the following conditions: 95°C for 2 min, 35 cycles of 95°C for 30 s, 63°C for 30 s (with a ramp of −0.75°C/cycle for the first 20 cycles and a constant temperature of 48°C for the remaining 15 cycles), 72°C for 20 s, and 72°C for 3 min. PCR products were purified using the QIAquick PCR Purification kit (QIAGEN) and subjected to heteroduplex formation using the following conditions in a thermocycler: 95°C 2 min, 95°C to 85°C (−2°C/s), and 85°C to 25°C (−0.1°C/s), and then digested with T7 endonuclease (NEB) for 20 min at 37°C. Digestion products were resolved on a 2% agarose gel. For Sanger sequencing, PCR products were cloned into pGEM-T easy (Promega).

### Allelic discrimination assay {#s15}

To distinguish WT from ZH3 alleles of *Prnp*, an amplicon encompassing the 8 bp deletion was generated in the presence of two TaqMan probes, each one specific for the WT or the ZH3 allele and carrying a different fluorophore at the 5′ end (FAM and Yakima Yellow, respectively) and the BHQ1 quencher at the 3′ end (primers and probes sequences in Table S2) using TaqMan Universal PCR Master Mix, No AmpErase UNG on a ViiA 7 Real-Time PCR System following a standard genotyping protocol (Life Technology).

### RFLP analysis {#s16}

To distinguish WT versus ZH3 alleles of *Prnp*, gDNA was PCR amplified using primers listed in Table S2. Amplicons were digested with Tsp45I, and digestion products were separated by electrophoresis on an agarose gel.

### G-banding and spectral karyotyping {#s17}

Mouse ear biopsies were cut into small pieces, and then incubated first with collagenase (Sigma-Aldrich) at 37°C for 1 h, and then with 0.05% Trypsin/0.53 mM EDTA (Wisent) at 37°C for 30 min. Cells were then cultured in α-MEM, 15% FBS, and antibiotics (GE Healthcare) for 1 wk, subcultured into 60-mm dishes until 80% confluence, incubated in 0.05 µg/ml colcemid (Invitrogen) for 20 min, trypsinized, pelleted, incubated in 75 mM KCl hypotonic solution at 37°C for 1 h, and fixed in 3:1 methanol/glacial acetic acid fixative. Mouse spleen was flushed with RPMI 1640, 250 mM Hepes, 10% FBS, 2 mM [l]{.smallcaps}-glutamine, and antibiotics (GE Healthcare), splenocytes were filtered, and cultured in the presence of 50 µg/ml LPS (Sigma-Aldrich) at 37°C for 72 h. Cells were then incubated in 0.05 µg/ml colcemid (Invitrogen) for 15 min, pelleted, incubated in 75 mM KCl hypotonic solution at 37°C for 1 h and fixed in 3:1 methanol/glacial acetic acid fixative. Cell suspensions were dropped onto slides in a Thermotron, aged overnight, G-banded and imaged, destained, denatured, and then hybridized overnight with denatured mouse spectral karyotyping reagent (Applied Spectral Imaging), washed, and counterstained with DAPI. For splenocytes, the steps for spectral karyotyping were omitted.

Image acquisition was performed with an Olympus BX61 microscope (Olympus) equipped with a SpectraCube SD300 (Applied Spectral Imaging) consisting of an optical head with a special Fourier-transform spectrometer, and a cooled CCD camera COOL-1300QS (VDS Vosskühler GmbH). Samples were illuminated with a xenon lamp Lambda LS (Sutter Instrument Company) through a Lambda 10-B optical filter changer with SmartShutter (Sutter Instrument Company) and imaged with a 60×/N.A. 1.42 oil immersion objective (Olympus). Images, typically consisting of a built from 128 frames of 600 ms, were acquired using Spectral Imaging acquisition software Version 4.5 (Applied Spectral Imaging). DAPI images were acquired separately. G-banded samples were imaged with a CCD camera (VDS Vosskühler GmbH) on the Olympus BX61 microscope set in bright-field mode with a 100×/N.A. 1.40 oil immersion objective (Olympus). To optimize contrast, a green filter was inserted in the illumination pathway. Spectral karyotyping images were analyzed using SkyView Version 2.1.1 (Applied Spectral Imaging).

### Array comparative genome hybridization {#s18}

gDNA was extracted from mouse tissue using QIAamp DNA mini kit (QIAGEN) and 1 µg of purified gDNA was labeled using the CytoSure Genomic DNA Labeling kit (Oxford Gene Technology), according to the manufacturers' instructions. Cy3-labeled C57BL/6J reference and cy5-labeled *Prnp^ZH3/ZH3^* experimental sample were hybridized with SurePrint G3 Mouse CGH Microarray kit, 1 × 1 M (Agilent Technologies) according to manufacturer's instructions. The 1 × 1 M array consists of 963,261 distinct 60-mer oligonucleotide probes, plus 1,000 replicates and an additional 6,745 quality control features, resulting in an 1.8-kb overall median spacing (1.5 kb in Ref-Seq genes; Agilent Technologies). Data were analyzed using Agilent Genomic Workbench 7.0.4.0 software (Agilent Technologies). Probes were annotated against the UCSC mm9 (NCBI Build 37) genome build. After a quality-control step, variant calling was performed using the aberration algorithm ADM-2 with the following filters: threshold 10.0, windows size 2 kb, diploid peak centralization ON, fuzzy zero ON, GC correction ON, combine replicates (intra-assay) ON, minimum number of probes 10, minimum average absolute log~2~ ratio ≥0.3.

### Whole-genome SNP analysis {#s19}

gDNA was purified from tail biopsies or ear punches using the Gentra Puregene Mouse Tail kit (QIAGEN) according to manufacturer's instructions. Whole-genome SNP analysis (Taconic Laboratories) was performed using the Illumina Mouse MD Linkage Panel array consisting of 1,449 strain-informative SNP markers spanning the whole genome (at least three SNPs every 5 Mb, with at least one SNP informative for C57BL/6J versus other strains; Illumina). Results were compared with data from reference strains (129S6/SvEvTac, C57BL/6JBomTac, and C57BL/6NTac).

### qRT-PCR {#s20}

RNA was isolated from snap frozen tissues using the RNeasy mini kit (QIAGEN). RNA concentration and quality were determined with NanoDrop (Thermo Fisher Scientific). Reverse transcription was performed using the QuantiTect Reverse Transcription kit (QIAGEN), according to the manufacturer's instructions. qRT-PCR was performed on a ViiA 7 Real-Time PCR System (Life Technology). Amplification was performed with Fast Start SYBR Green Master (ROX; Roche) with 0.5 µM of each forward and reverse primers for the target of interest or appropriate normalization genes (Table S2) and cDNA as template, using the following conditions: 50°C for 2 min, 95°C for 10 min, 40 cycles of 95°C for 15 s, and 60°C for 1 min. After each run, a melting curve analysis was performed, using the following conditions: 95°C for 15 s, 60°C for 1 min, and 95°C for 15 s. For all steps, a ramp rate of 1.6°C/s was used. Raw Ct values were used to calculate relative expression levels of target genes, after normalization to three internal control genes (*Eif2a*, *Utpc6*, and *Gapdh*) according to geNorm ([@bib49]). *Eif2a* and *Utpc6* primer sequences were originally reported in ([@bib28]); *Gapdh* primer sequences were obtained from the Genomics Platform--University of Geneva.

### RNA sequencing {#s21}

Mice under deep anesthesia were transcardially perfused with ice-cold PBS heparin treated with diethylpyrocarbonate. Hippocampi were immediately dissected with the help of an adult mouse brain slicer matrix (Zivic Instruments), snap frozen, and kept --80°C until homogenization. Total RNA was isolated using the RNeasy Plus universal mini kit (QIAGEN), snap frozen, and kept at --80°C until further analysis. Library preparation for RNA sequencing was performed, as previously described ([@bib35]) with modifications. RNA quality was assessed using Bioanalyzer 2100 (Agilent Technologies) and Qubit (1.0) Fluorometer (Life Technologies). Only samples with a 28S/18S ratio between 1.5 and 2 and a 260 nm/280 nm ratio between 1.8 and 2.1 were further processed. The TruSeq RNA Sample Prep kit v2 (Illumina) was used in the subsequent steps. In brief, 1 µg of total RNA per sample was poly A--enriched, reverse transcribed into double-stranded cDNA and ligated with TruSeq adapters. PCR was performed to selectively enrich for fragments containing TruSeq adapters on both ends. Quality and quantity of enriched libraries were analyzed using Qubit (1.0) Fluorometer and Caliper GX LabChip GX (Caliper Life Sciences). The resulting product is a smear with a mean fragment size of ∼260 bp. Libraries were normalized to 10 nM in Tris-Cl 10 mM, pH 8.5, with 0.1% (vol/vol) Tween 20.

TruSeq PE Cluster kit v4-cBot-HS (Illumina) was used for cluster generation using 2 pM of pooled normalized libraries on the cBOT. Sequencing was performed on Illumina HiSeq 2500 at 1 × 100 bp using the TruSeq SBS kit v4-HS (Illumina).

RNA sequencing data analysis was performed as previously described ([@bib35]), with minor modifications. Reads were quality-checked using FastQC. Low-quality ends were clipped (5′, 3 bases; 3′, 10 bases). Trimmed reads were aligned to the reference genome and transcriptome (FASTA and GTF files, respectively, downloaded from the Ensembl GRCm38) with STAR version 2.3.0e_r291 ([@bib16]) with default settings. Loci with mismatches with respect to the reference genome were detected following the best practice workflow to identify variants from RNA sequencing data using GATK version 3.4.0 ([@bib15]). This analysis was performed on the three mice with the highest sequencing coverage for each group and only mismatches in common to all three mice in each group were considered. Sequence mismatches were dichotomized as either RNA-editing sites if present in a previously published catalog of 17\`831 RNA editing sites in mice ([@bib45]) or otherwise as variants. Variants were annotated using snpEFF version 3.4 ([@bib11]), and distribution of the reads across genomic isoform expression was quantified using the R package GenomicRanges ([@bib29]) from Bioconductor Version 3.0. DEGs were identified based on fdr values using the R package edgeR ([@bib38]) from Bioconductor Version 3.0. Differential exon usage was detected based on adjusted P values with the DEXSeq R-package ([@bib2]) using default parameters. Visualization of RNA sequencing coverage was performed using Integrative Genome Viewer ([@bib37]). Pathway analysis was performed using Ingenuity Pathway Analysis (Ingenuity Systems). Data from RNA sequencing analyses have been deposited to GEO under the dataset code [GSE75510](GSE75510){#dblnk3dfc21a2-545c-5220-44b0-6411fdfa46ed}.

A list of genes enriched in neurons, astrocytes, oligodendrocytes, microglia and CNS endothelial cells (500 genes per cell type) was retrieved using the cell type enrichment query from a transcriptomic based database, ([@bib50]), searching for genes enriched in one cell type respect to all others. In the case of oligodendrocytes, oligodendrocytes precursor cells, newly formed oligodendrocytes and myelinating oligodendrocytes were considered together. The resulting, nonoverlapping lists of CNS cell type enriched genes were used for comparisons with the lists of genes with differential gene expression, exon usage, and RNA editing in the present study.

### Sequencing of gDNA {#s22}

GDNA was extracted as from tissue biopsies using a buffer containing 10 mM Tris-HCl, pH 9.0, 50 mM KCl, 0.45% Nonident p40, 0.45% Tween-20 and Proteinase K. Target regions were amplified by PCR using appropriate primers (listed in Table S2) under the following conditions: 2 min at 94°C; 35 cycles of 30 s at 94°C, 30 s at 58°C, and 45 s at 72°C; 5 min at 72°C. Amplicons were subjected to agarose gel electrophoresis and DNA was purified from excised bands using the Nucleospin Gel and PCR Cleanup kit (Macherey-Nagel), according to manufacturer's instructions. Sanger sequencing was performed at Microsynth AG, using the same primer pair used for PCR amplification.

### Western blotting {#s23}

Snap-frozen tissues were used to prepare 10% (w/vol) homogenates in RIPA buffer (25 mM Tris-HCl, pH 7.6, 150 mM NaCl, 1% Nonident p40, 1% sodium deoxycholate, and 0.1% SDS) + cOmplete Mini Protease Inhibitor Cocktail (Roche) using 5-mm stainless steel beads (QIAGEN) and Tissue Lyser LT (QIAGEN). Total protein concentration was measured using the BCA Protein Assay (Thermo Fisher Scientific) according to the manufacturer's instructions. 20 µg of total protein homogenates in NuPAGE LDS sample buffer (Invitrogen) with β-mercaptoethanol as reducing agent were separated on a NuPAGE 12% Bis-Tris (Invitrogen) and transferred onto a Protran Nitrocellulose Transfer Membrane (Whatman) using the NuPAGE Gel Electrophoresis System (Invitrogen) according to the manufacturer's instructions. Precision Plus Protein Dual Color Standards (Bio-Rad Laboratories) and MagicMark XP Standard to Antibodies (Invitrogen) were used as molecular weight ladder. Membranes were subsequently blocked with 5% w/vol Top-block (Fluka) in TBS supplemented with 0.1% vol/vol Tween-20 (TBST). Antibodies were incubated in 1% wt/vol Top-block (Fluka) in TBST. Primary antibodies used were: anti-PrP^C^ mouse monoclonal antibodies POM1 (280 ng/ml; [@bib36]) and anti-actin mouse monoclonal antibody, Clone C4 (1:8,000; EMD Millipore). HRP-conjugated goat anti--mouse IgG (H+L; 1:17,000 dilution; Invitrogen) was used as secondary antibody. Blots were developed using Luminata Western HRP Substrates (EMD Millipore) and visualized using the Stella detector (Raytest).

### PrP^C^ ELISA {#s24}

PrP^C^ was quantified in tissue homogenates by sandwich ELISA using POM1 and POM2 antibodies as previously described ([@bib36]).

### Footprint test {#s25}

The footprint test was performed as previously described ([@bib7]), with minor modifications. To obtain footprints, the fore and hind feet of the mice were painted with magenta and blue nontoxic inks, respectively. Mice were then allowed to walk along a 90-cm long, 7-cm wide, 20-cm high corridor on a fresh white paper. Mice had up to three trials. Footprints were analyzed for the following parameters, as previously described ([@bib7]): stride length (mean distance of footprints from the same paw in consecutive strides); hind-base width (mean distance between right and left hind footprints); front-base width (mean distance between right and left front footprints); and front/hind footprint overlap (mean distance between hind footprint and the preceding front footprint). Footprints at the beginning and at the end of the corridor were excluded. For each step parameter, 4--12 values were measured and the mean was calculated and used for analysis. The operator was blind to mouse genotype.

### Rotarod test {#s26}

The rotarod test was performed as previously described ([@bib43]), with minor modifications. The rotarod apparatus consisted of a rotating cylinder (ø 3 cm) subdivided into five 57-mm-wide lanes by dividers (ø 25 cm; Ugo Basile). Each test comprised a habituation phase and an experimental phase. The habituation phase consisted of three sessions of 1 min each, at a constant speed of 5 rotations per minute (rpm), with inter-session intervals of at least 15 min. The test phase, which started at least 15 min after the last habituation trial, consisted of three sessions of maximum 5 min each, at a constant acceleration from 5 rpm to maximum of 40 rpm, with inter-session intervals of at least 15 min. Falling from the drum or clinging to the rod and passively rotating with it were equally considered to assess latency to fall. Rotarod tests were performed at the same time of the day (between 2 p.m. and 4 p.m.), with a 1-mo interval. In each cage, mice were randomly tested and the operator was blind to their genotype.

### Histology, immunohistochemistry, and immunofluorescence {#s27}

Hematoxylin and eosin stainings were performed on sections from formalin-fixed, paraffin-embedded tissue using standard protocols. CD68 staining was performed on 7--10 µm cryo-sections from snap-frozen sciatic nerves embedded in OCT medium as previously described ([@bib5]). After fixation with formalin and acetone solutions, sections were incubated with rat anti--mouse CD68 monoclonal antibody (1:100 dilution, clone FA-11; Serotec), followed by incubation with goat anti--rat IgG (1:150 dilution; Antibodies Online), and donkey anti--goat IgG conjugated with alkaline phosphatase (1:80 dilution; Jackson ImmunoResearch Laboratories). Immunoreactivity was visualized using the mix Fast Red staining kit (Sigma-Aldrich). Toluidine blue staining was performed using standard procedures on semi-thin sections (500 nm) from epon-embedded sciatic nerves that had been fixed in situ with 3.9% glutaraldehyde in 0.1 M PBS, pH 7.4, after transcardial perfusion with PBS. In all cases, slides were scanned with NanoZoomer and images were visualized using the NanoZoomer Digital Pathology System (NDPview; Hamamatsu Photonics). For morphometric analysis of CD68^+^ digestion chambers in sciatic nerves, at least 10 regions of interest per section were selected from a total of two to four sections per mouse. For morphometric analysis of axonal density in sciatic nerves, at least three regions of interest per section were selected from three to nine sections per mouse. Images were analyzed using semiautomatized softwares developed in-house. Operators were blind to the genotype of the analyzed cases.

Immunofluorescence stainings were performed on sections from formalin-fixed, paraffin-embedded tissue. After deparaffinization through graded alcohols and heat-induced antigen retrieval in citrate buffer (0.01 M, pH 6.0), sections were incubated with anti-POM19 (20 µg/ml; [@bib36]) and MAP2 (1:500; Abcam) antibodies, followed by incubation with fluorescently labeled secondary antibodies (1:1,000; Alexa Fluor 488 or 555; Invitrogen) and with DAPI (Life technologies) for nuclear staining. Images were acquired with the fluorescence microscope (BX-61; Olympus) equipped with a cooled black/white charge-coupled device camera, using identical acquisition settings.

In all cases, images were prepared using Photoshop and Illustrator software (Adobe).

### Transmission electron microscopy {#s28}

Mice under deep anesthesia were transcardially perfused with PBS heparin and sciatic nerves were then fixed in situ with 2.5% glutaraldehyde + 2% paraformaldehyde in 0.1 M PBS, pH 7.4. Tissues were then embedded in epon, and semi-thin sections (500 nm) were stained with toluidine blue using standard procedures. Ultrathin sections were mounted on copper grids coated with Formvar membrane and contrasted with uranyl acetate/lead citrate. Specimens were examined using a Hitachi H-7650 electron microscope (Hitachi High-Tech) operating at 80 kV.

### Phagocytosis assay with BM-derived macrophages (BMDMs) {#s29}

On day 1, femurs of age-matched adult males were flushed with culture medium (RPMI 1640, 10% FBS, 1% Glutamax and antibiotics; all from GE Healthcare). BM cells were and plated into 6-well plates (TPP) at a density of 2 × 10^6^/well in 3-ml culture medium enriched with 10 ng/ml of murine macrophage colony-stimulation factor (Invitrogen) and cultured overnight at 37°C and 5% CO~2~. On day 2, nonadhering cells were transferred to a Nunc UpCell Surface cell culture dish (Sigma-Aldrich). On day 6, the resulting BMDMs were harvested, adjusted to 5 × 10^5^ cells in 500 µl, and plated into 24-well plates. On the same day, thymocytes were harvested from 6--12-wk-old C57BL/6 mice and incubated overnight at 37°C and 5% CO~2~ in culture medium in the presence of 0.1 µM dexamethasone to induce apoptosis. On day 7, thymocyte apoptosis was assessed using the FITC Annexin V Apoptosis Detection kit II (BD). Apoptotic thymocytes were washed, suspended at 10^6^/ml in PBS, and labeled with 20 ng/ml of the pH-sensitive dye pHrodo Red, SE (Invitrogen) for 30 min at room temperature. Labeled thymocytes were washed and resuspended in culture medium to achieve different cellular densities, and then 500 µl of cell suspension were added to each well of the BMDM culture for 1 h at 37°C. After washing, BMDMs were harvested with Stem Pro Accutase (Invitrogen) and gentle scraping, and subsequently stained with FITC-labeled anti-CD11b or isotype control antibody (BD). Flow cytometry was performed using a FACSCalibur (BD) with CellQuestPro software. At least 10,000 events were acquired in the living gate. Rate of phagocytosis was determined with FlowJo software (Tree Star) as the percentage of pHrodo positivity among CD11b^+^ cells.

### Statistical analysis {#s30}

Statistical significance was assessed using GraphPad Prism software with two-tailed unpaired Student's *t* test or one- or two-way ANOVA and Bonferroni's multiple comparison post-test, as appropriate. α level was set at 0.05. For each statistical analysis, the statistical test, the group size and the resulting p-value are indicated in the corresponding figure legends.

### Online supplemental material {#s31}

Fig. S1 shows that C57BL/6J-*Prnp^ZH3/ZH3^* mice do not have chromosomal aberrations. Fig. S2 shows whole-genome SNP analysis. Fig. S3 shows *Prnp* mRNA coverage. Fig. S4 shows Sanger sequencing of selected genomic sites undergoing RNA editing. Fig. S5 shows flow cytometry analysis of phagocytic activity. Table S1 lists Predicted TALEN OTs analyzed. Table S2 lists primers and probes used. Table S3 lists DEGs between *Prnp^ZH1/ZH1^* and C57BL/6J hippocampi. Table S4 lists DEGs between *Prnp^ZH3/ZH3^* and C57BL/6J hippocampi. Table S5 lists differentially expressed exons between *Prnp^ZH1/ZH1^* and C57BL/6J hippocampi. Table S6 lists loci with differential RNA editing level between *Prnp^ZH1/ZH1^* and C57BL/6J hippocampi. Table S7 lists loci with differential RNA editing level between *Prnp^ZH3/ZH3^* and C57BL/6J hippocampi. Online supplemental material is available at <http://www.jem.org/cgi/content/full/jem.20151610/DC1>.
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